Table 1.
Patient and donor characteristics.
| Patient/Donor ID | Sex | Age | Disease Characteristics/Donor Information |
|---|---|---|---|
| AML_033 | f | 61 | AML FAB M4, Complex aberrant karyotype, negative for FLT3-ITD, NPM1, CEBPA |
| AML_036 | m | 66 | sAML from CMML, trisomy 8, deletion 21q, duplication 15q11/15q26, negative for FLT3-ITD, NPM1, CEBPA |
| AML_037 | f | 60 | AML FAB M5, normal karyotype, FLT3-ITD+, NPM1 mutation type D |
| AML_044 | m | 71 | AML FAB M1, normal karyotype, negative for FLT3-ITD, NPM1, CEBPA |
| AML_049 | f | 18 | AML FAB M1, normal karyotype, FLT3-ITDlow, negative for NPM1, CEBPA |
| DON_004 | m | 39 | all donors passed a medical work-up and were released for stem cell donation; the following conditions were excluded: active infections such as viral hepatitis, AIDS, syphilis, malaria; history of malignant tumors or systemic autoimmune diseases; medically significant abnormalities of the differential blood count |
| DON_005 | f | 25 | |
| DON_011 | f | 40 | |
| DON_012 | m | 44 | |
| DON_013 | m | 20 |
Abbreviations: FAB, French American British Classification; wt, wild type; FLT3-ITD, fms-like tyrosine kinase 3-internal tandem duplication; NPM1, Nucleophosmin 1; sAML, secondary acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; CEBPA, CCAAT/enhancer-binding protein alpha; FLT3-ITDlow, ratio of the mutant to wild type allele <0.5.